GSK3145095   Click here for help

GtoPdb Ligand ID: 12245

Synonyms: compound 6 [PMID: 31223438] | GSK-3145095
PDB Ligand
Compound class: Synthetic organic
Comment: GSK3145095 is an orally bioavailable receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor [1]. It was developed for potential antineoplastic and immunomodulatory activities, but development was terminated at Phase 2.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 5
Topological polar surface area 99.77
Molecular weight 397.38
XLogP 3.65
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C1Nc2c(CC[C@@H]1NC(=O)c1n[nH]c(n1)Cc1ccccc1)cc(cc2F)F
Isomeric SMILES C1Cc2c(c(cc(c2)F)F)NC(=O)[C@H]1NC(=O)c1n[nH]c(n1)Cc1ccccc1
InChI InChI=1S/C20H17F2N5O2/c21-13-9-12-6-7-15(19(28)25-17(12)14(22)10-13)23-20(29)18-24-16(26-27-18)8-11-4-2-1-3-5-11/h1-5,9-10,15H,6-8H2,(H,23,29)(H,25,28)(H,24,26,27)/t15-/m0/s1
InChI Key ATQAGKAMBISZQM-HNNXBMFYSA-N
No information available.
Summary of Clinical Use Click here for help
GSK3145095 was advanced to clinical evaluation for anti-tumour potential.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03681951 First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors Phase 2 Interventional GlaxoSmithKline Development of GSK3145095 was terminated during the monotherapy dose escalation phase of this study.